secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001558370-24-005060
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path expands global patent portfolio with new patents in Mexico, Australia, Japan
--------------------------------------------------------------------------------

- Received newly issued patents in Mexico (IGF-1R inhibition), Australia (STAT3, IGF-1R, BCL2 inhibition), and Japan (liposomal formulation).
- Portfolio now includes 5 issued US patents and 54 foreign patents covering 21 countries.
- Expects six additional patent grants this year; 51 pending applications across six families.
- Patents protect DNAbilize antisense platform and provide 20 years of exclusivity for new targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024005060/0001558370-24-005060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024005060/bpth-20240415x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-005060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer